The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods
Open accessAbstract
The first report of Staphylococcus aureus with intermediate-level resistance to vancomycin (VISA) was from Japan in 1997 (20), raising the threat of incurable staphylococcal infections. Since then, a number of cases have been reported worldwide, with eight confirmed cases in the United States as of June 2002 (9, 13). The majority of these cases have occurred in patients who have had prolonged exposure to vancomycin (13). Furthermore, the majority of these strains appear to have evolved from methicillin-resistant S. aureus (MRSA) strains previously infecting the patient, a conclusion that may be drawn from the similarities observed between the pulsed-field gel electrophoresis patterns of the VISA strains and the preexisting MRSA strains (12, 34). Fortunately, since emerging 6 years ago, infection with VISA is still a rare event. However, the phenomenon of vancomycin heteroresistance in S. aureus (hVISA) has been described more frequently in the literature, although the best method to detect hVISA strains and their clinical significance are ill-defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 1×
“The first report of Staphylococcus aureus with intermediate-level resistance to vancomycin (VISA) was from Japan in 1997 (20), raising the threat of incurable staphylococcal infections.”
BackgroundHiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Staphylococcus aureus resistant to vancomycin--United States, 2002.
(2002) · PubMed · Cited by 569
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414 · cited 6×
“Figure 1 illustrates typical population analysis curves for VRSA, VISA, hVISA, and VSSA.”
MethodInfluentialVancomycin for Staphylococcus aureus endocarditis in intravenous drug users
Small, P. M., & Chambers, H. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1227 · Cited by 399
Self-citationIncreasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Hanaki, H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.199 · Cited by 366
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344 · cited 2×
“Since then, a number of cases have been reported worldwide, with eight confirmed cases in the United States as of June 2002 (9, 13).”
BackgroundWalsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., & Diekema, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2439-2444.2001 · Cited by 319
Weinstein, R. A., & Fridkin, S. K. (2001) · Clinical Infectious Diseases · doi:10.1086/317542 · Cited by 304
Production of l-DOPA by Aspergillus terreus
Chattopadhyay, S., & Das, A. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb03888.x · Cited by 243
The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
Hiramatsu, K. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00149-1 · Cited by 191
Geisel, R. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.6.846 · Cited by 181
Ariza, J., Pujol, M., Cabo, J., Peña, C., Fernández, N., Liñares, J., Ayats, J., & Gudiol, F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01017-x · Cited by 167
Bacteremia Caused by Staphylococci with Inducible Vancomycin Heteroresistance
Wong, S. S. Y., Ho, P. L., Woo, P. C. Y., & Yuen, K. Y. (1999) · Clinical Infectious Diseases · doi:10.1086/520429 · Cited by 165
Moore, M. R., Perdreau‐Remington, F., & Chambers, H. F. “. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1262-1266.2003 · Cited by 149
Self-citationVancomycin-Intermediate Staphylococcus aureus in Korea
Kim, M., Pai, C. H., Woo, J. H., Ryu, J. S., & Hiramatsu, K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3879-3881.2000 · Cited by 142
Trakulsomboon, S., Danchaivijitr, S., Rongrungruang, Y., Dhiraputra, C., Susaemgrat, W., Ito, T., & Hiramatsu, K. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.2.591-595.2001 · Cited by 130
Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates
Boyle‐Vavra, S., Berke, S. K., Lee, J. C., & Daum, R. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.272-277.2000 · Cited by 126
Marchese, A. E., Balistreri, G., Tonoli, E., Debbia, E. A., & Schito, G. C. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.866-869.2000 · Cited by 123
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections
Moise, P. A., & Schentag, J. J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00303-4 · Cited by 118
Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany
Bierbaum, G., Fuchs, K., Lenz, W., Szekat, C., & Sahl, H. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050380 · Cited by 114
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
Khurshid, M., Chou, T. D., Carey, R. A., Larsen, R. A., Conover, C. S., & Bornstein, S. (2000) · MMWR Morbidity and Mortality Weekly Report · Cited by 109
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 84
Bobin-Dubreux, S., Reverdy, M. E., Nervi, C., Rougier, M., Bolmström, A., Vandenesch, F., & Étienne, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.349-352.2001 · Cited by 70
Brunet, F. P., Vedel, G., Dreyfus, F., Vaxelaire, J. F., Giraud, T., Schremmer, B., & Monsallier, J. F. (1990) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963643 · Cited by 60
Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin
Wong, S. S. Y., Ng, T. K., Yam, W.-C., Tsang, D. N., Woo, P. C. Y., Fung, S. K. S., & Yuen, K. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00141-8 · Cited by 57
Καντζάνου, Μ., Tassios, P. T., Tseleni-Kotsovili, A., Legakis, N. I., & Vatopoulos, A. C. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.5.729 · Cited by 55
Vancomycin-Intermediate Staphylococcus aureus in a Home Health-Care Patient
Hageman, J. C., Pegues, D. A., Jepson, C., Bell, R. L., Guinan, M. E., Ward, K. W., Cohen, M. D., Hindler, J. A., Tenover, F. C., McAllister, S. K., et al. (2001) · Emerging infectious diseases · doi:10.3201/eid0706.010618 · Cited by 55
Reverdy, M. E., Jarraud, S., Bohin-Duhreux, S., Buret, E., Girardo, P., Lina, G., Vandenesch, F., & Étienne, J. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1198-743x.2001.00256.x · Cited by 54
Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus
Howe, R. A., Wootton, M., Walsh, T. R., Bennett, P. M., & MacGowan, A. P. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.5.675 · Cited by 52
Franchi, D., Climo, M. W., Wong, A. H. M., Edmond, M. B., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/313530 · Cited by 51
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
(2000) · PubMed · Cited by 50
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationDavid, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Metadata
- Authors
- Liu, C., & Chambers, H. F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-10
- Volume
- 47
- Issue
- 10
- Pages
- 3040-3045
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2137097355
- Cited by
- 321
- References
- 42
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.